Literature DB >> 21321149

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.

Helio S Sader1, Paul R Rhomberg, David J Farrell, Ronald N Jones.   

Abstract

CXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam), and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-characterized clinical strains collected worldwide, including ceftazidime-resistant members of the family Enterobacteriaceae and Klebsiella pneumoniae carbapenemase (KPC)- and extended-spectrum β-lactamase (ESBL)-producing strains of Pseudomonas aeruginosa and Bacteroides fragilis. CXA-201 was 2- to 32-fold more active than ceftazidime and piperacillin-tazobactam against ceftazidime-resistant Enterobacteriaceae species but less active than cefepime for some species. CXA-101 and CXA-201 were very active against P. aeruginosa (MIC50, 1 μg/ml for both compounds), including imipenem-resistant strains.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21321149      PMCID： PMC3088243          DOI： 10.1128/AAC.01737-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Authors:  Yigong Ge; M J Whitehouse; Ian Friedland; George H Talbot
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa.

Authors:  Shinobu Takeda; Yoshikazu Ishii; Kazuo Hatano; Kazuhiro Tateda; Keizo Yamaguchi
Journal:  Int J Antimicrob Agents       Date:  2007-07-17       Impact factor: 5.283

3.  In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

Authors:  Catharine C Bulik; Henry Christensen; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

4.  Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae.

Authors:  Mariana Castanheira; Helio S Sader; Ronald N Jones
Journal:  Microb Drug Resist       Date:  2010-03       Impact factor: 3.431

5.  Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.

Authors:  David M Livermore; Shazad Mushtaq; Yigong Ge
Journal:  J Antimicrob Chemother       Date:  2010-06-30       Impact factor: 5.790

6.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

7.  Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; Laura Zamorano; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

8.  Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

Authors:  David M Livermore; Shazad Mushtaq; Yigong Ge; Marina Warner
Journal:  Int J Antimicrob Agents       Date:  2009-05-09       Impact factor: 5.283
  8 in total
  44 in total

Review 1.  Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.

Authors:  Young R Lee; Danni McMahan; Catherine McCall; Gregory K Perry
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 2.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

3.  In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Authors:  A Walkty; J A Karlowsky; H Adam; M Baxter; P Lagacé-Wiens; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

4.  Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.

Authors:  Gopi Patel; Meenakshi M Rana; Shirish Huprikar
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

5.  Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Authors:  Christopher Lucasti; Ellie Hershberger; Benjamin Miller; Sara Yankelev; Judith Steenbergen; Ian Friedland; Joseph Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

Review 6.  Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias.

Authors:  Q Q Wan; Q F Ye; H Yuan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-12       Impact factor: 3.267

Review 7.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

8.  Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.

Authors:  Ana Motos; Gianluigi Li Bassi; Francesco Pagliara; Laia Fernandez-Barat; Hua Yang; Eli Aguilera Xiol; Tarek Senussi; Francesco A Idone; Chiara Travierso; Chiara Chiurazzi; Rosanel Amaro; Minlan Yang; Joaquim Bobi; Montserrat Rigol; David P Nicolau; Gerard Frigola; Roberto Cabrera; Jose Ramirez; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antonio Artigas; Jordi Vila; Marin Kollef; Antoni Torres
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

9.  Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Authors:  Bartolomé Moyá; Alejandro Beceiro; Gabriel Cabot; Carlos Juan; Laura Zamorano; Sebastián Alberti; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

10.  Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Authors:  A J Lepak; A Reda; K Marchillo; J Van Hecker; W A Craig; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.